未成熟卵培養授精形成胚胎後先予冷凍，未來解凍植入可達較高懷孕率

多囊性卵巢病患，未施打hCG 破卵針下取出未成熟卵，於hMG 500iu/ml培養後授精形成胚胎後，可先予冷凍，在未來週期解凍後再植入可達較高懷孕率




from: http://www.ncbi.nlm.nih.gov/pubmed/21868003

Fertil Steril. 2011 Oct;96(4):860-4. Epub 2011 Aug 24.

Clinical outcome of non-hCG-primed oocyte in vitro maturation treatment in patients with polycystic ovaries and polycystic ovary syndrome.

De Vos M, Ortega-Hrepich C, Albuz FK, Guzman L, Polyzos NP, Smitz J, Devroey P.

Source

Center for Reproductive Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium. mdv@uzbrussel.be

Abstract

OBJECTIVE:

To compare clinical outcomes of fresh embryo transfer (ET) and vitrified-warmed ET in an artificial endometrial priming cycle in patients with polycystic ovaries (PCO) or polycystic ovary syndrome (PCOS) who underwent oocyte in vitro maturation (IVM) in non-hCG-primed cycles.

DESIGN:

Prospective cohort study.

SETTING:

University-based tertiary referral center.

PATIENT(S):

Thirty-nine consecutive patients <37 years old with PCO or PCOS, who underwent 73 cycles of immature oocyte retrieval.

INTERVENTION(S):

Immature oocyte collection after ovarian stimulation with a cumulative dose of 450 IU uFSH or highly purified hMG, but without hCG priming. IVM of oocytes followed by ET if endometrium thickness ≥ 6 mm. Embryo vitrification at the cleavage stage. ET in an artificial cycle.

MAIN OUTCOME MEASURE(S):

Implantation rate (IR) and clinical pregnancy rate (CPR).

RESULT(S):

Fresh ET after IVM resulted in an IR of 6.9% (5/72) per ET and a CPR of 9.4% (5/53). ET of vitrified-warmed IVM embryos in an artificial cycle resulted in significantly better outcomes (IR 21.9% [7/32] and CPR 31.8% [7/22] per ET).

CONCLUSION(S):

A non-hCG-primed IVM system in PCO or PCOS performs poorly when embryos are transfered in a fresh cycle. Transfer of vitrified-warmed IVM embryos in an artificial cycle leads to significantly improved clinical outcomes. These data illustrate that IVM embryos in PCO or PCOS have good survival rates and suggest that hCG may be needed to support endometrial receptivity in the fresh IVM cycle.